Another upcoming study will examine denosumab in ovarian cancer patients with BRCA1 mutation, using immunohistochemistry of patient samples measuring Ki67 as a proliferation index to compare proliferation in denosumab vs. control groups [115]. This evidence concerns the gene BRCA1 and ovarian cancer.